Cell and Life Therapeutics is developing next-generation small-molecule medicines to target the RNA cycle for treating neurodegenerative and oncology disorders. In collaboration with Jubilant Biosys, Cell and Life Therapeutic has established “STAR (Small-molecule TArgeting RNA biology)” library platform. Recently Cell and Life Therapeutic has selected a preclinical candidate for muscle atrophy diseases […]
Kerentech
9 posts
We are proud to announce that our client EmstoPA has received the Regulatory Endorsement of Development Program by British MHRA and US FDA: The Medicines & Healthcare Products Regulatory Agency have recently reviewed and endorsed EmstoPA’s Plan, providing excellent feedback on each aspect. FDA has also reviewed and provided positive feedback for […]
BREN-02 is expected to be administered in clinical trials in ALS patients in the second half of 2021, subject to preclinical toxicity results and regulatory review. Preclinical studies have shown that the homeoprotein hEN1 is essential for the survival and maintenance of spinal cord alpha motor neurons that innervate muscles […]
GoodGut has signed an agreement with Palex Medical to start selling its new non-invasive diagnostic tests RAID-Dx for irritable bowel syndrome (IBS) and RAID-Monitor for inflammatory bowel disease (IBD) in Spain. These are the first products developed by GoodGut to reach the patient after ten years of R&D and clinical […]
ABAC Therapeutics Announces €16 Million Series A to develop therapeutic solutions to fight antibiotic-resistant bacteria BARCELONA, Spain – February 15th, 2018 — ABAC Therapeutics (ABAC), a leader in pathogen-specific antibiotics, announced today the closing of a €16 million Series A round. The financing was led by Pontifax with participation from […]
Eloxx Pharmaceuticals Secures US$8 Million Investment from LSP, Increasing Total Raised in Series C to US$38 million August 2, 2017 Financing to support advancement of novel disease-modifying therapy targeting genetic diseases, including cystic fibrosis SAN DIEGO and REHOVOT, Israel, Aug. 2, 2017 /PRNewswire/ — Sevion Therapeutics, Inc. (OTCQB: SVON) and Eloxx Pharmaceuticals […]
